Concurrent Chemoimmunotherapy in Metastatic Clear Cell Sarcoma: A Case Report

Lauro, Salvatore; Bordin, F.; Trasatti, L.; Lanzetta, Gaetano; Rocca, Carlo Della; Frati, Luigi

doi:10.1177/030089169908500617

Cited by 20 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Steger et al [17] reported a 17-month complete response to perilesional interferon alpha 2b (administered for 4 months) in a 40-year-old woman with CCS, but there have been few other reports of the use of immunotherapy in this disease [18].…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy in clear cell sarcoma

et al. 2010

View full text Add to dashboard Cite

Clear cell sarcoma is a rare translocation-related sarcoma. There have been few studies documenting the response rate and progression-free survival in clear cell sarcoma patients treated with palliative chemotherapy. The prospectively maintained databases of two referral centres were searched to identify clear cell sarcoma patients treated with chemotherapy. Twenty-four patients were treated with palliative first-line chemotherapy with a median age of 30 years at diagnosis. There were 18 men and 6 women. One (4%) achieved a partial response and 9 (38%) had stable disease. Fourteen patients (58%) progressed on therapy. The median progression-free survival was 11 weeks (95% CI, 3–20 weeks). The median overall survival from commencing first-line chemotherapy was 39 weeks (95% CI, 34–45 weeks). Second-line chemotherapy was administered to 12 patients, 11 (92%) of these progressed and one (8%) had stable disease. Of the 5 patients treated with third-line chemotherapy, 4 (80%) progressed and one (20%) had stable disease. One patient received fourth-line chemotherapy and maintained stable disease for 4 months. Conventional chemotherapy has minimal activity in clear cell sarcoma as documented by the response rate of 4% and median progression-free survival of 11 weeks in this retrospective series. These data provide a reference for response and outcome in the assessment of novel agents in this histological subtype.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapy in clear cell sarcoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…There is anecdotal evidence of clinical activity of interferon-alpha 2b in the setting of metastatic CCS. One patient achieved SD during 17 months after simultaneous treatment with subcutaneous interferon-alpha 2b and six courses of cyclophosphamide, vincristine, doxorubicin, and dacarbazine (CYVADIC) [46].…”

Section: Immunotherapymentioning

confidence: 99%

Biology and management of clear cell sarcoma: state of the art and future perspectives

Cornillie

Cann

Woźniak

et al. 2016

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

In this review, we systematically discuss the current scientific evidence for the systemic treatment of CCS, including tyrosine kinase inhibitors, immunotherapy and MET inhibitors. Expert commentary: Recent insights in the biology of CCS have identified new potential therapeutic targets, which should be tested in prospective clinical trials. Whenever possible, patients with metastatic CCS should be included in clinical trials with good biological rationale. Innovative trial methodology and new regulatory mechanisms are required to provide patients with uncommon cancers with active drugs.

show abstract

“…There have been case reports of responses to interferon in osteosarcoma [14, 15] and complete responses in clear cell sarcomas [16, 17]. From 1971 to 1990, 89 consecutive patients with localized high-grade osteosarcoma received adjuvant therapy with interferon- α .…”

Section: Nonspecific Immunomodulationmentioning

confidence: 99%

Immune-Based Therapies for Sarcoma

Pollack

Loggers

Rodler

et al. 2011

Sarcoma

View full text Add to dashboard Cite

Immunotherapy has shown promise in a number of tumor types, but its exact role in sarcoma remains to be defined. Advanced bone and soft tissue sarcomas are challenging diseases to treat with an unmet need for effective systemic therapy. Previous reports have suggested that immune-based treatments may be effective in sarcoma, but such approaches have not yet become part of standard clinical practice. A number of sarcoma subtypes express targets known as cancer testis antigens and hence may be excellent targets for immunotherapy. This paper will focus on the recent advances and understanding of cancer testis antigens in sarcoma and also clinical data of immunotherapeutic approaches in these diseases.

show abstract

Concurrent Chemoimmunotherapy in Metastatic Clear Cell Sarcoma: A Case Report

Cited by 20 publications

References 15 publications

Chemotherapy in clear cell sarcoma

Chemotherapy in clear cell sarcoma

Biology and management of clear cell sarcoma: state of the art and future perspectives

Immune-Based Therapies for Sarcoma

Contact Info

Product

Resources

About